Reviewer’s report

Title: Efficacy of combined treatment with pasireotide, pegvisomant and cabergoline in an acromegalic patient resistant to other treatments: a case report.

Version: 0 Date: 01 Oct 2017

Reviewer: Adriana Ioachimescu

Reviewer’s report:

This a case report of a 41 year old man with acromegaly who underwent several regimens of medical therapy and surgery and achieved biochemical control for the first time on a combination of pasireotide LAR/pegvisomant.

I have the following comments:

- Abstract: Include patient's age instead of "young acromegalic". Also the fact this was a mixed GH/PRL pituitary adenoma.

- Background: the long sentence on lines 79-82 requires streamlining. Sentence on lines 86-87 would me more informative if it included a range of IGF-1 normalization from several published studies rather than "up to 97%".

- Case presentation:

  What happened to the prolactin level in absence of dopamine agonist regimen?

  Line 108, replace "from some months" with "for some months". Line 114: replace "objectivity" with "exam". Line 122: replace "larger diameter" with "largest diameter". Line 129" "slight increase in fasting glucose and HbA1c" is not quite accurate as HbA1c increased from 5.9 to 6.5%. Line 138: "Surgery proved unsuccessful" could be replaced with something more adequate. The tumor was invasive to the cavernous sinus, so surgery had a debulking rather than a curative purpose. In addition, it did significantly improved the biochemical parameters of acromegaly, which increased the likelihood of control on postoperative medical treatment, which is what actually happened. Line 151: replace "highlighted" with "seen". Line 158: replace "with more colliquative outcomes" with something more appropriate that reflects changes in signal on the MRI.

- Discussion: line 199: Delete "Surprisingly" because doses of pegvisomant were not escalated to the maximally-allowed and injections were not daily.

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

Yes
Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

Unable to assess

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.

Yes

Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

Not relevant to this manuscript

Quality of written English
Please indicate the quality of language in the manuscript:

Acceptable

Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.
My institution has received funding for multicentric research trials/registries and investigator-initiated research from Ipsen, Novartis and Pfizer. I was the principal investigator for those studies. I received consulting fees from Ipsen, Novartis and Pfizer for my participation in advisory boards.

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal.